24th edition of the Human Proteome Organization World Congress | HUPO WORLD 2025
November 9 ā 13, 2025 | Toronto, Canada
AFFINISEP BREAKFAST SEMINAR
Innovative SPE Kits for Sample Preparation in MS-Based Proteomics
Wednesday, November 12, 2025 | 8:00 - 9:00 AM
Wednesday, November 12, 2025 | 8:00 - 9:00 AM
Sample Preparation methods for Glycoproteomics and Phosphoproteomics based on Affinisep BioSPEĀ® membrane: Top-down Phospho-code analysis and automated workflow for N-glycan profiling
This seminar will present innovative Affinisep SPE kits designed to streamline sample preparation in MS-based proteomics. Dr. Che-Fan Huang from the Proteomics Center of Excellence at Northwestern University will highlight their use in developing a method for top-down phospho-code analysis, while Klaus Lindpaintner, M.D., from Bruker will showcase a liquid biopsy platform for N-glycan profiling. Together, these talks will demonstrate practical applications of BioSPEĀ® solutions to improve reliability and efficiency in proteomics workflows.
First, Dr. Che-Fan (Jeffrey) Huang will present his work: Towards a Catenin Phospho-Code for Adherens Junction Organization via Top-Down Proteomics.
Authors: Che-Fan Huang(1), Taojunfeng Su(1), Jeanne M. Quinn(2), Cara J. Gottardi(2),(3), Neil L. Kelleher(1)
1: Proteomics Center of Excellence, Northwestern University, Evanston, IL.
2: Department of Pulmonary Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
3: Department of Cell & Developmental Biology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Register for Affinisep Breakfast Seminar
Register and secure your seat now!
Please note that you will automatically be enrolled in our monthly newsletter by registering.
Unsubscribe at any time.
Affinisep develops and manufactures from A to Z high quality and ready-to-use microelution BioSPEĀ® kits to simplify sample preparation in proteomics workflows and help you achieve highly reliable results. Our wide range of formats and capacities allow us to cover a broad range of needs, from a few samples processed manually, to high throughput processing of hundreds of samples in clinical studies.
Then, Klaus Lindpaintner will talk about N-glycan profiling of Immunoglobulin G for Systemic Lupus Erythematosus disease course classification using the GlycoTyper Liquid Biopsy Platform.
Authors: Gray Huffman(1), Grace Grimsley(1), Aaron Angerstein(2), Tamara Nowling(3), Richard Drake(2), Steve Castellino(1), Klaus Lindpaintner(1)
1: Glycobiology Solutions, Bruker Scientific Inc.,
2: Department of Cell and Molecular Pharmacology, Medical University of South Carolina
3: Division of Rheumatology & Immunology, Medical University of South Carolina
SPEAKERS' INFORMATION
ā¶ Che-Fan (Jeffrey) Huang, Ph.D.
Dr. Che-Fan (Jeffrey) Huang, a native of Taiwan, is a postdoctoral scholar at the Proteomics Center of Excellence at Northwestern University. His current research focuses on top-down proteomics, mass spectrometry, and chemical biology, with an emphasis on biomarker discovery and proteoform-level insights into human disease and cellular mechanisms. He received his Ph.D. in Chemistry from Northwestern University, where he combined surface engineering and MALDI mass spectrometry to study phosphatases; and holds both B.S. and M.S. degrees from National Taiwan University, where he first grew interests in proteomics.
ā· Klaus Lindpaintner, MD, MPH
Klaus Lindpaintner, MD, MPH, VP and Global Head of Glycobiology Solutions at Bruker Daltonics, previously held senior positions at Pfizer as Global Head, Human Genetics and Computational Biomedicine, at Hoffman-La Roche as Director, Roche Center for Medical Genomics, as CSO at Thermo-Fisher-Scientific, as CSO/CMO at Intervenn, a plasma glycoproteomics company, and on the faculty of Harvard Medical School. Klaus has co-authored approximately 250 scientific publications and holds honorary and adjunct professorships at several academic institutions. He serves on numerous boards, working groups, and advisory panels for professional organizations, regulatory agencies, and non-governmental organizations on issues related to the successful implementation of novel technologies in healthcare, with a particular focus on precision medicine. Klaus holds a medical degree from the University of Innsbruck and a graduate degree in public health from Harvard University. He pursued post-graduate training and specialization in internal medicine, cardiology, and clinical and molecular genetics, and is a diplomate of the boards in these specialties. His lifelong interest and passion has been the application of innovative science and technology to personalized medicine.